RedHill is an emerging pharmaceutical company focused on developing, acquiring, in-licensing, and launching commercial stage drugs within the specialty/gastrointestinal disease space. I lead and facilitated the launch of Talicia encapsulated Minitabs, in-licensed and re-launched Aemcolo solid oral dosage tablets, and acquired Movantik during my tenure.Directed the successful launch of Talicia and was accountable for all commercial supply chain activities in the United States inclusive of supplier selection, qualification, and supply agreement executions as well as DSCSA compliance, 3PL rollout, and commercial manufacturing management.Spearheaded the supply chain and commercial manufacturing due diligence activities in acquiring Movantik, which included the negotiation and execution of supply, license, and tech transfer agreements along with the overall strategic plan to successfully onboard Movantik with RedHill livery, subsequent formulation and packaging tech transfers, supplier selections and supply agreement executions and ultimately, a multi-phased approach to securing a complex virtual supply chain under cost control and proper life cycle management.Advanced the launch of Aemcolo in the United States under a commercial in-license platform with a strategic partner in the EU. This included the successful management and implementation of a commercial supply agreement, all commercial manufacturing activities, DSCSA compliance, child resistance testing, and the re-launch of Aemcolo under RedHill livery in the United States.

Kala is a successful start-up company focused on launching Loteprednol ophthalmic suspension, targeting dry eye disease and post-surgical ocular inflammation and pain. I facilitated the successful launch of Inveltys ophthalmic suspension during my time at Kala.Built the functional incorporation of a full-service 3PL provider with comprehensive Customer Service, Accounts Receivable, Inventory and Warehouse Management, Returns, and Quality Management functions.Developed a cross-functional Sales and Operations Plan (S&OP) inclusive of launch planning scenario builds, long-range supplier forecasts, budget builds, and quality resource constraints/opportunities. Plan utilizes the Assumptions/Risks/Actions model to better facilitate company-wide accountability and internal/external communications platforms.Advanced the planned rollout of the tenet-based EPCIS software for the Drug Supply Chain & Security Act (DSCSA or ePedigree) project acting as the Company driver for DSCSA compliance and Team Lead.

Cempra was a startup biopharmaceutical company focused on launching their lead antibiotic drug candidate, Solithromycin in oral and IV formulations, into the global marketplace to treat community-acquired bacterial pneumonia (CABP).Responsible for the global supply chain build and strategy for Solithera and Taksta antibiotics representing pre-launch 2016 expenditures of ~$50MM USD inclusive of a commercial launch plan across a complex virtual supply base.Ensured long-range BARDA supply plans across several epidemic/outbreak levels while ensuring consistent and fiscally responsible inventory levels across a complex and long lead time-based supply chain. Safeguarded product life cycle management against supply agreement terms, patent cliffs, product competition/events, capacity, and budgetary modeling as well as long-range supplier Procurement Plans.Created fiscally responsible supply and demand models within the confines of pre-commercial volatility while adhering to strategic product launch objectives.Worked to mitigate inventory risk by identifying single-source versus dual-source suppliers and constructing a robust supply base for critical items. Owned the Drug Supply Chain & Security Act (DSCSA or ePedigree) project acting as the Company driver for DSCSA compliance and Team Lead.Conducted gap analysis of the Customs Compliance Program and developed internal Customs Compliance Program.Established a commercial communication platform for supplier relationship management inclusive of out licensing partners and a complex multi-tiered supply base.

Salix was a successful high-growth and mid-cap-sized company focused on several leading gastrointestinal drugs for the global market and was highly successful in launching, acquiring, and licensing several key products before being acquired in 2015 for $11 billion USD.Directed a completely virtual Supply Chain of 70+ suppliers and providers for 40+ NDC commercial products representing over $1 billion in sales and $300 million dollars in purchases annually.Proactively implemented a cross-functional Sales and Operations Plan (S&OP) that enabled visibility and control of supply and demand up and down the organization while empowering decisions to drive change and accountability while lowering inventory carrying costs 40% on average across the product portfolio.Represented company on several Alliance/Business Review Meetings representing company interests in royalties, in-licensing, out-licensing, authorized generics, business development, quality reviews, product portfolio changes, obsolescence, yields analysis, capacity build-outs, annual price increase/discounts, contractual negotiations, and long-range planning.Successfully built a Supply Chain and Logistics group inclusive of three Supply Chain Managers, a Logistics Manager, and a Director of Strategic Sourcing and Procurement.Owned the strategic sourcing and procurement process inclusive of RFQ/RFI, term sheet negotiation, and supply contract negotiations leading to valued supplier relationships, quality products, and fiscal control.Skillfully negotiated and executed several high-dollar supply and manufacturing agreements for API, finished packaging, and finished goods inclusive of both out-sourced and in-sourced goods across pharmaceuticals, medical devices, combo drugs, authorized generics, and development agreements.Promoted from Director of Global Supply Chain and Logistics to Executive Director Global Supply Chain and Logistics.

Orexigen was a promising pharmaceutical company focused on the clinical development and commercial approval of prescribed weight control medications, Contrave and Empatic, for the US market.Responsible for the overall supply chain execution for Contrave and Empatic inclusive of clinical supply, API supply, and pre/post-commercial production across multiple third-party suppliers.Proactively sourced primary and secondary suppliers for multiple commercial API launch requirements and subsequently negotiated and executed four API supplier contracts creating key partnerships while securing capacity needs for Orexigen’s two lead drug candidates at pre-launch.Adeptly negotiated the price and receipt of API for discounts totaling $1MM USD for use within pre-commercial manufacturing and CMO site qualifications.Skillfully negotiated and executed multi-site CMO, clinical trial service, and commercial packaging supply contracts and aligned services within corporate budgets and objectives for pre-commercial products.Facilitated the design and execution of several commercial label and package designs in collaboration with Orexigen’s commercialization partner.Sourced and helped identify overt/covert anti-counterfeiting and anti-diversion technology for use on commercial products.Proactively facilitated the use of retained outside counsel for legal advice on the shipment of products (API and Finished Goods) into the US as well as intra-U.S. (within States).

Sunovion is a prosperous mid-cap pharmaceutical company that successfully launched such drugs as Lunesta, Brovana, and Xopenex.Responsible for the overall supply chain management of Lunesta, Xopenex, and Brovana Finished Goods and API representing over $1 billion in sales and $60 million dollars in purchases.Proactively implemented a fully integrated S&OP process with the leadership role of managing the planning, procurement, consigned inventory, production, and logistics of multiple API processing sites and CMO’s across several 3PL sites.Effectively assessed shortfalls in long and short-range manufacturing capacities at contract manufacturers and organized cross-functional teams to address opportunities to mitigate supply risk against inventory targets. These include the initiation of sourcing secondary contract manufacturers and the restructuring of existing manufacturing service agreements to better align with long-range supply strategy and capacity output.Team Leader for weekly/monthly cross-functional teams that address the strategy and tactics of the S&OP as well as short and long-range production schedules and capacity plans, production forecasts, purchase orders, and any resulting projects that affect the overall manufacturing output of Finished Goods, API’s and components.Promoted from Supply Manager to Senior Manager of Product Supply.